ClinicalTrials.gg
RecruitingNCT01762813ACROBATICCUpdated Apr 30, 2026

Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer

An observational study in Colorectal Cancer, sponsored by Helse Stavanger HF. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Helse Stavanger HF · Observational

How we know

From the registry’s dates

  • Started Jan 2013; still recruiting 13 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Colorectal Neoplasms with a site in Norway — 19 open to participants now, 35 under way, 6 of them phase 3. Colorectal Neoplasms · Norway.

Planned enrollment
4th of 12
1,200 · median 427
Started
2013
with 1 other
Observational
12 of 82
4 open now
Primary completion
2035-12
later than 31 of 34 live
Registered
31st of 82
by date
Lead sponsor
2 of 82
Helse Stavanger HF

Among the 82 studies in Colorectal Neoplasms with a site in Norway, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2013, is one of 12 observational ones, reaches primary completion later than 31 of the 34 other live ones, and was the 31st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

19 of the 82 studies in Colorectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Colorectal Neoplasms with a site in Norway, or all of them as a file.
02

Study summary

  • A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer
  • Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary cancers and/or normal colon
Read the detailed description

Prospective project in collecting and assessing clinical outcomes data related to molecular profiling of tumors based on cancer primary or metastatic tissue or tissue from peripheral blood samples. As a future part of the project will be collected patient reported outcomes (PROs) for assessing clinical outcomes in relation to clinical pathways, patient reported results, as well as tumor profiling by molecular methods.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colon cancer
  • rectal cancer
  • liver metastasis
  • survival
  • biomarker
  • molecular profile
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with colorectal cancer (primary and/or secondary) undergoing surgery for curative intent

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of colorectal cancer, primary or (liver), with a treatment intention of planned curative surgery
  • to participate
  • Age ≥18

Exclusion criteria

Exclusion Criteria:

  • failure to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • open and laparoscopic surgery

    Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.

    Procedure: open and laparoscopic surgery

Interventions

  • Procedureopen and laparoscopic surgery

    Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)

    Also known as: Liver surgery

06

What researchers measure

Primary outcomes

  1. Cancer-specific survival

    Time from surgery to death of cancer

    Time frame: 5-years

Secondary outcomes

  1. Recurrence-free survival

    Time from surgery to recurrence of cancer

    Time frame: 3 and 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Soreide K, Watson MM, Lea D, Nordgard O, Soreide JA, Hagland HR; ACROBATICC collaborators. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis. J Transl Med. 2016 Jun 29;14(1):192. doi: 10.1186/s12967-016-0951-4. PubMed 27357108 ↗
  • Hagland HR, Lea D, Watson MM, Soreide K. Correlation of Blood T-Cells to Intratumoural Density and Location of CD3+ and CD8+ T-Cells in Colorectal Cancer. Anticancer Res. 2017 Feb;37(2):675-683. doi: 10.21873/anticanres.11363. PubMed 28179316 ↗
  • Watson MM, Lea D, Hagland HR, Soreide K. Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. Transl Oncol. 2019 Dec;12(12):1583-1588. doi: 10.1016/j.tranon.2019.08.009. Epub 2019 Oct 31. PubMed 31677491 ↗
  • Watson MM, Kanani A, Lea D, Khajavi RB, Soreide JA, Korner H, Hagland HR, Soreide K. Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival. Ann Surg Oncol. 2020 Apr;27(4):1058-1067. doi: 10.1245/s10434-019-08048-6. Epub 2019 Nov 4. PubMed 31686344 ↗
  • Lea D, Zaharia C, Soreide K. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores. Cancer Treat Res Commun. 2024;38:100788. doi: 10.1016/j.ctarc.2023.100788. Epub 2023 Dec 22. PubMed 38150845 ↗
  • Watson MM, Lea D, Gudlaugsson E, Skaland I, Hagland HR, Soreide K. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer. Cancer Immunol Immunother. 2020 Aug;69(8):1627-1637. doi: 10.1007/s00262-020-02573-0. Epub 2020 Apr 20. PubMed 32314040 ↗
  • Veen T, Kanani A, Alvestad AB, Edland KH, Lea D, Soreide K. Rectal cancer with synchronous liver metastasis undergoing hepatectomy: sequencing to the 'liver-first' reflects tumour burden of the primary. Surg Oncol. 2026 Jun;66:102413. doi: 10.1016/j.suronc.2026.102413. Epub 2026 Mar 23. PubMed 41886837 ↗
  • Veen T, Lea D, Roalso M, Soreide K. Repeat hepatectomy for colorectal liver metastasis with rates of second and third hepatectomy: time-to-recurrence and overall survival in a population-derived cohort. HPB (Oxford). 2026 Feb;28(2):189-198. doi: 10.1016/j.hpb.2025.11.006. Epub 2025 Nov 14. PubMed 41372018 ↗
  • Kanani A, Veen T, Lea D, Zaharia C, Watson M, Alexeeva M, Thorsen K, Soreide K. Neoadjuvant Immunotherapy Followed by Surgery Compared with Upfront Surgery Alone in Operable Colon Cancer with Deficient Mismatch Repair: Modeling Oncological Outcomes and Numbers Needed to Treat. Ann Surg Oncol. 2025 May;32(5):3068-3077. doi: 10.1245/s10434-024-16755-y. Epub 2024 Dec 30. PubMed 39738901 ↗
  • Veen T, Kanani A, Zaharia C, Lea D, Soreide K. Treatment-sequencing before and after index hepatectomy with either synchronous or metachronous colorectal liver metastasis: Comparison of recurrence risk, repeat hepatectomy and overall survival in a population-derived cohort. Eur J Surg Oncol. 2025 Feb;51(2):109540. doi: 10.1016/j.ejso.2024.109540. Epub 2024 Dec 9. PubMed 39662106 ↗

Individual participant data

Plan to share: Undecided — Raw data may be provided given appropriate consent and approval for anonymous database sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2013 (actual). Primary completion is estimated for Dec 2035, 275 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 275 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2013
First posted
Jan 8, 2013
StartActual
Jan 1, 2013
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2036
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01762813
Lead sponsor
Helse Stavanger HF
Responsible party
Sponsor
First posted
Jan 8, 2013
Start date
Jan 1, 2013
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Apr 30, 2026

Study contacts

Ramesh L. Kajavi, RN
Contact
acro.gitan@gmail.com
92297672 ext. 47
Marina Alexeeva, PhD
Contact
marina.alexeeva@sus.no
Kjetil Søreide, MD, PhD, FRCS, FACS
principal investigator · Helse Stavanger HF

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion